Progenesis is a San Diego-based company founded in 2015 that develops and offers non-invasive genetic tests for patients on their family planning journey. We offer a variety of services that can be customized to meet the needs of every patient we serve. The Progenesis team is a motivated group of genetic specialists, researchers, laboratory professionals, and analysts who are passionate about improving our patients' lives. As pioneers in genetic screening technologies, our scientists are constantly pursuing research initiatives to advance our services and expand our understanding of human genetics.
Address: 4150 Regents Park Row Suite 245 La Jolla, CA 92037
Novelvi® is an advanced noninvasive prenatal screening test (NIPT) used to determine chromosomal status during pregnancy. The test can be performed as early as 10 weeks into pregnancy to safely screen for aneuploidy using a blood sample from the mother. Professional societies, including the American Congress of Obstetricians and Gynecologists (ACOG), have recommended NIPT as an option for all pregnant women, regardless of age or risk.
Novelvi® is a non-invasive prenatal test that analyzes cell-free DNA (cfDNA) from maternal blood to check for chromosomal abnormalities (aneuploidy). cfDNA are fragments of DNA that circulate in the bloodstream; a pregnant mother has a percentage of her cfDNA that originates from the fetus.
As early as 10 weeks into pregnancy, cfDNA may be obtained from the mother’s blood and used to screen for certain chromosomal abnormalities.
Each chromosome has segments that are unique to that chromosome, enabling scientists to link or map sequences of DNA to specific chromosomes. Novelvi® works by sequencing and then measuring the amount of cfDNA that comes from each chromosome. Higher or lower levels of cfDNA mapping back to a particular chromosome may indicate aneuploidy.
In NIPT, test failure is essentially an inconclusive result. This can be frustrating for many families and prompts some patients to pursue invasive follow-up procedures in search of a definitive result.
Novelvi® helps you avoid this stress by using massive parallel sequencing (MPS) to bring you the lowest rate of test failure and results you can trust.